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Introduction {#sec001}
============

Antiretroviral therapy (ART)-associated metabolic derangement and metabolic syndrome (MetS) are more prevalent than ART-associated toxicities such as lactic acidosis, peripheral neuropathies, cardiomyopathies, and pancytopenia \[[@pone.0226573.ref001]--[@pone.0226573.ref005]\]. In adults, MetS is defined as having at least three out of five of the following components: impaired fasting glucose or diabetes, hypertension, central obesity (increased waist circumference), elevated triglycerides or reduced high-density lipoprotein (HDL) cholesterol \[[@pone.0226573.ref006]\]. The prevalence of MetS in people living with HIV (PLWH) is as high as 83%, particularly in PLWH on protease inhibitors (PI)-based regimens \[[@pone.0226573.ref007]\], compared to 34% in the general population \[[@pone.0226573.ref008]\]. MetS has been associated with an increased risk of cardiovascular diseases (CVDs) such as myocardial infarction (MI), atherosclerosis, and stroke \[[@pone.0226573.ref009], [@pone.0226573.ref010]\].

The high prevalence of MetS and CVDs in PLWH may be due to a complex interplay of HIV infection \[[@pone.0226573.ref011], [@pone.0226573.ref012]\], ART exposure, other viral co-infections \[[@pone.0226573.ref013], [@pone.0226573.ref014]\], and traditional risk factors such as genetic predisposition genetics \[[@pone.0226573.ref015]\] and lifestyle habits. However, the underlying mechanisms are not well known. We recently observed that CEM cells exposed to 1x- and 4x-C~max~ of various antiretroviral combinations resulted in differential expressions of 122 out of 48,226 genes using microarray analysis (published \[[@pone.0226573.ref016]\] and unpublished data). Over a third of those genes belonged to the cholesterol biosynthesis pathway. Based on our findings, we hypothesized that ART could perturb cholesterol biosynthesis genes before manifestation of overt signs and symptoms of lipid abnormalities and MetS. We investigated the effect of ART on cholesterol biosynthesis in peripheral blood mononuclear cells (PBMCs) of HIV treatment-experienced individuals (cases) compared to HIV-negative healthy individuals (controls).

We interrogated four major pathways genes involved in cholesterol regulation using mRNA and protein expression studies: sensory control (sensor sterol regulatory element binding protein 2, SREBP-2), de novo synthesis (3-hydroxy-3-methylglutaryl-coenzyme A reductase, HMGCR), cholesterol uptake (low-density lipoprotein receptor, LDLR), and efflux (ATP binding cassette transporter A1, ABCA1). We also measured the expression of AMP-activated protein kinase A1 & B2 (AMPK A1 & AMPK B2, precursors of the cholesterol synthesis pathway.

Materials and methods {#sec002}
=====================

Study participants and procedures {#sec003}
---------------------------------

Study participants were enrolled at the Yale-New Haven Hospital from April 2011 to March 2013. The details of the study design for this cohort have been described previously \[[@pone.0226573.ref017]\]. In brief, for this cholesterol sub-study, cases comprised HIV-infected individuals on ART for at least 12 months without clinical and/or laboratory toxicities including MetS. Cases were matched by age, sex, and race/ethnicity to HIV-negative controls. All participants gave their written informed consent before participation in the study. The study protocol was approved by the Institutional Review Board of the Yale School of Medicine.

At study enrollment, participants answered a brief survey comprised of demographic characteristics and past medical history. Medical records of HIV-infected participants were reviewed, and disease characteristics and laboratory data (complete blood count, serum chemistries, liver function test, lipid profile, urinalysis, HIV RNA copy number, and CD4+ T-cell count) were extracted. Each participant gave about 20 ml of venous blood at the time of enrollment. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood within 2 hours of collection using Ficoll gradient (Ficoll-Hypaque; ICN) as described previously \[[@pone.0226573.ref018]\]. Aliquots of PBMCs were stored at -80°C until RNA extraction for cholesterol biosynthesis pathway gene expression experiments, and Western blot analysis. This sub-study included only study participants with sufficient archived PBMCs for the analysis (cases, n = 18, and controls, n = 18).

RNA isolation and cholesterol biosynthesis gene expression assay {#sec004}
----------------------------------------------------------------

RNA was isolated from PBMCs using the TRIzol^®^ Reagent Kit according to the manufacturer's instructions as previously described \[[@pone.0226573.ref019]\], after which quantitative real-time PCR (qRT-PCR) was performed for mRNA expressions of cholesterol biosynthesis genes (see [Table 1](#pone.0226573.t001){ref-type="table"} for primer sequences): SREBP-2, HMGCR, LDLR, ABCA1, AMPK A1 and AMPK B2. The housekeeping gene encoding glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control for all reactions. Melting curve analysis was conducted on the qRT-PCR output to ensure that no false-positive results were included in the analysis. Data were obtained from at least two independent experiments with duplicates in each experiment. The fold change in gene expression was calculated as 2^-Δ*CT*^, where Δ*CT*~(case)~ = (*CT*~(gene\ of\ interest)~ − *CT*~(GAPDH)~), and Δ*CT*~(healthy\ control)~ = (*CT*~(gene\ of\ interest)~ − *CT*~(GAPDH)~).

10.1371/journal.pone.0226573.t001

###### Primer sequence.

![](pone.0226573.t001){#pone.0226573.t001g}

  ---------------------------------------------------------------------------------------------------------------------------------------
  Gene Name                                                 Gene ID   Reference Sequence   Forward\                        Product Size
                                                                                           Reverse                         
  --------------------------------------------------------- --------- -------------------- ------------------------------- --------------
  Sterol regulatory element binding protein 2               SREBP2    NM_004599            `5′-TGGCTTCTCTCCCTACTCCA-3′`\   153
                                                                                           `5′-GAGAGGCACAGGAAGGTGAG-3′`    

  HMG coenzyme reductase A                                  HMGCR     NM_000859            `5’-TTCGGTGGCCTCTAGTGAGA-3’`\   99
                                                                                           `5’-GATGGGAGGCCACAAAGAG-3’`     

  Low-density lipoprotein receptor                          LDLR      NM_000527            `5'-GCTTGTCTGTCACCTGCAAA-3'`\   190
                                                                                           `5′-AACTGCCGAGAGATGCACTT-3'`    

  Adenosine triphosphate--binding cassette transporter A1   ABCA1     NM_005502            `5'-AACAGTTTGTGGCCCTTTTG-3'`\   156
                                                                                           `5'-AGTTCCAGGCTGGGGTACTT-3'`    

  AMP Kinase A1                                             AMPK A1   NM_006251            `5’-ACCTTCGGCAAAGTGAAGG-3’`\    96
                                                                                           `5’-CACATCAAGGCTCCGAATCT-3’`    

  AMP Kinase B2                                             AMPK B2   NM_005399            `5’-GTGTTCAGCCTCCCTGACTC-3’`\   125
                                                                                           `5’-CCTTCAGACCAGCGGATAAC-3’`    
  ---------------------------------------------------------------------------------------------------------------------------------------

Western blot analysis of protein expression of cholesterol biosynthesis genes {#sec005}
-----------------------------------------------------------------------------

Western blot analysis was performed as described previously \[[@pone.0226573.ref020]\] using total cell protein extracts from PBMCs. Measurements were conducted on participants with sufficient samples for western blot analysis (controls, n = 8; and cases, n = 8). Tubulin was used as the housekeeping gene. Primary antibodies: HMGCR and ABCA1 were used at 1:2000 (Abcam, Cambridge, MA); secondary antibodies were HRP conjugated anti-rabbit antibodies anti-mouse antibodies at 1:2000 and 1:5000, respectively (Cell Signaling Technology, Danvers, MA). Enhanced chemiluminescence substrate was used for signal development (PerkinElmer, Shelton, CT). Quantity One Analysis Software was used to quantify band density from the films.

Statistical analysis {#sec006}
--------------------

We report data as medians with 25^th^-- 75^th^ percentile interquartile ranges (unless otherwise stated) and as frequencies with percentages for continuous and categorical variables, respectively. We used the Wilcoxon signed-rank test to compare continuous variables and a linear regression model to examine associations. P-values were considered significant if \<0.05. All statistical analyses were performed using GraphPad Prism software.

Results {#sec007}
=======

Characteristics of study participants {#sec008}
-------------------------------------

The demographic and clinical characteristics of study participants are illustrated in [Table 2](#pone.0226573.t002){ref-type="table"}. The mean age was 53 years (range, 38 to 72 years), with 67% being males. The race/ethnicity comprised 28% non-Hispanic whites, 6% Hispanic white and 66% African Americans. The ART regimen of the cohort was mostly tenofovir/emtricitabine (33%) plus a protease inhibitor (PI) or an integrase inhibitor, tenofovir/emtricitabine/efavirenz (50%) and zidovudine/lamivudine (17%).

10.1371/journal.pone.0226573.t002

###### Demographic and clinical characteristics of study participants.

![](pone.0226573.t002){#pone.0226573.t002g}

  Variable                                                                    HIV un-infected individuals (Controls, n = 18)   HIV infected individuals on antiretroviral therapy (Cases, n = 18)
  ------------------------------------------------------ -------------------- ------------------------------------------------ --------------------------------------------------------------------
  Mean Age (Range), years                                                     53 (38--72)                                      53 (38--72)
  Gender                                                 Male                 12                                               12
  Female                                                 6                    6                                                
  Race                                                   White non-Hispanic   5                                                5
  White Hispanic                                         1                    1                                                
  African American                                       12                   12                                               
  Mean CD4 count (range) (count/μL)                                           N/A                                              735 (264--1159)
  Mean Viral load (range) (copies/mL)                                         N/A                                              23 (20--79)
  Mean Duration of exposure to treatment (range) (yrs)                        N/A                                              4.77 (1--7.5)
  Treatment Regimen (%)                                  NRTI                 N/A                                              9
  NRTIs/NNRTI                                            N/A                  9                                                
  Mean Cholesterol (range)                                                    N/D                                              175 (72--248)
  Mean HDL (range)                                                            N/D                                              52 (25--82)
  Mean LDL (range)                                                            N/D                                              99 (9--158)
  Mean Triglycerides (range)                                                  N/D                                              129 (56--258)

N/A, not applicable

N/D, not determined for healthy volunteers

NRTI, Nucleoside Reverse Transcriptase Inhibitor

NNRTI, Non-nucleoside Reverse Transcriptase Inhibitor

mRNA expression of cholesterol biosynthesis genes in study participants {#sec009}
-----------------------------------------------------------------------

Elevated cholesterol levels are associated with foam cell development and an increased risk of cardiovascular events \[[@pone.0226573.ref021]\]. We quantified the mRNA expression of genes involved in cholesterol biosynthesis- SREBP-2, HMGCR, LDLR, and ABCA1 as well as genes involved in the signaling of cellular energy states- AMPK A1 and AMPK B2 using qRT-PCR. Samples from cases (treatment-experienced PLWH) and controls (individuals without HIV) were used in this quantification. HMGCR and ABCA1 mRNA expression levels were upregulated in cases compared to healthy controls (p = 0.03 and p\<0.01, respectively) ([Fig 1](#pone.0226573.g001){ref-type="fig"}). There was no significant difference in SREBP-2 expression among cases and controls, although cases tended to have a lower expression of SREBP-2 and AMPK B2 compared to healthy controls. Similarly, there was no statistically significant difference in the expression of LDLR and AMPK A1 between cases and controls.

![mRNA and protein expression of cholesterol biosynthesis genes in peripheral blood mononuclear cells (PBMCs) of participants.\
HIV positive individuals on ART (cases, n = 18) and HIV negative individuals (controls, n = 18). A. mRNA expression of Sterol response element binding protein 2 (SREBP-2). B. mRNA expression of HMG coenzyme reductase A (HMGCR). C. mRNA expression of Low-density lipoprotein receptor (LDLR). D. mRNA expression of Adenosine triphosphate--binding cassette transporter A1 (ABCA1). E. mRNA expression of AMP Kinase A1 (AMPK A1). F. mRNA expression of AMP Kinase A2 (AMPK A2). Protein expression of cholesterol biosynthesis genes in PBMCs of HIV positive individuals on ART (cases: N = 8) and HIV negative individuals (controls: N = 8). The density of the bands was quantified using Quantity One Analysis Software. Data are median (25^th^-- 75^th^ percentiles of interquartile range), p values represent Wilcoxon matched-pairs signed-rank test, with significance being p \< 0.05. G. protein expression of HMGCR. H. protein expression of ABCA1.](pone.0226573.g001){#pone.0226573.g001}

Protein expression of cholesterol biosynthesis genes in study participants {#sec010}
--------------------------------------------------------------------------

With the significant increase in mRNA expressions of HMGCR and ABCA1 in cases, we investigated whether this translated to protein expressions. Western blot analysis was performed as described previously \[[@pone.0226573.ref020]\] using tubulin as the housekeeping gene. The Western blot analysis was conducted on 16 participants with sufficient samples (cases n = 8 and controls n = 8). We observed a corresponding increase in protein expression of HMGCR (p = 0.02), however the ABCA1 expression levels did not attain statistical significance (p = 0.05) in cases ([Fig 1G and 1H](#pone.0226573.g001){ref-type="fig"}). To exclude the possibility that the sub-group of patients with adequate cells whose protein expression levels were quantified represented a non-random sampling, we compared the mRNA expression levels of the patients with and without protein expression level results and found no statistically significant difference ([Fig 2](#pone.0226573.g002){ref-type="fig"}).

![mRNA expression levels in patients with protein expression level results (western blots (WB)) compared to those without (No WB) to determine whether included participants were comparable to excluded participants.\
A. Controls- mRNA expression comparison of HMGCR. B. Cases- mRNA expression comparison of HMGCR. C. Controls- mRNA expression comparison of ABCA1. D. Cases- mRNA expression comparison of ABCA1. n = 10 (No WB-), n = 8 (WB). Data are median (25^th^-- 75^th^ percentiles of interquartile range), p values represent Wilcoxon matched-pairs signed-rank test, with significance being p \< 0.05.](pone.0226573.g002){#pone.0226573.g002}

Correlation of cholesterol biosynthesis genes in study participants {#sec011}
-------------------------------------------------------------------

In health, there is a positive correlation between SREBP-2 and HMGCR as well as SREBP-2 and LDLR \[[@pone.0226573.ref022], [@pone.0226573.ref023]\]. Therefore, with differential upregulation of HMGCR and ABCA1 in cases and controls, we investigated the correlation between SREBP-2 and HMGCR, and SREBP-2 and LDLR. As expected in controls (N = 18), there was a positive correlation between SREBP-2 and HMGCR (R^2^ = 0.24, p = 0.04), and LDLR (R^2^ = 0.23, p = 0.05) ([Fig 2](#pone.0226573.g002){ref-type="fig"}). To our surprise, the correlations among the cases were negative ([Fig 3](#pone.0226573.g003){ref-type="fig"}). Even when the outlier in [Fig 3D](#pone.0226573.g003){ref-type="fig"} was excluded, the data still reflected a negative correlation in cases (data not shown).

![Correlation analysis of mRNA expression of cholesterol biosynthesis genes in peripheral blood mononuclear cells (PBMCs) of participants.\
HIV positive individuals on ART (cases, n = 18) and HIV negative individuals (controls, n = 18). Linear regression analysis was performed and significance was noted for p values \< 0.05. R^2^ values are reported for correlations with significance. A. The mRNA expression of SREBP-2 vs. HMGCR in controls. B. The mRNA expression of SREBP-2 vs. HMGCR in cases. C. The mRNA expression of SREBP-2 vs. LDLR in controls. D. The mRNA expression of SREBP-2 vs. LDLR in cases.](pone.0226573.g003){#pone.0226573.g003}

Discussion {#sec012}
==========

ART is associated with adverse effects and toxicities that can significantly decrease clinical efficacy \[[@pone.0226573.ref024]\], however, the underlying molecular mechanisms are under-studied. We measured the expression levels of genes involved in cholesterol biosynthesis and found an upregulation of HMGCR and ABCA1. There was corresponding increase in protein expressions of HMGCR. Correlation studies confirmed the previously documented relationship between the genes in healthy individuals. In health, there is a positive correlation between SREBP-2 and HMGCR as well as SREBP-2 and LDLR \[[@pone.0226573.ref022], [@pone.0226573.ref023]\]. However, cases, HIV treatment-experienced individuals, were notable for negative correlations. Thus, ART (and perhaps the HIV virus) is likely involved in the dysregulation of cholesterol biosynthesis prior to clinical and laboratory manifestations of hyperlipidemia in PLWH. HMGCR and ABCA1 could serve as biomarkers to predict the onset of cholesterol dysregulation.

Under physiologic conditions, if intracellular levels of cholesterol become low, SREBP-2 is cleaved from the endoplasmic reticulum (ER) and migrates into the nucleus \[[@pone.0226573.ref025]\] causing increased expression of HMGCR (the rate-limiting step in the synthesis of cholesterol) and LDLR (a membrane-associated cholesterol receptor) \[[@pone.0226573.ref026]\] and decreased expression of ABCA1 (a cholesterol efflux protein). These regulatory mechanisms ensure cellular homeostasis. If there is an intracellular accumulation of cholesterol, the expression of ABCA1 is increased to facilitate reverse cholesterol transport out of the cell \[[@pone.0226573.ref027]\]. HIV infection disrupts cholesterol efflux by ABCA1, however, there is no consensus on the effect of subsequent introduction of ART on ABCA1 expression \[[@pone.0226573.ref028], [@pone.0226573.ref029]\].

ABCA1 is a member of a superfamily of ATP-binding cassette (ABC) transporters that are involved in transporting molecules across cellular membranes. ABCA1 is involved with exporting phospholipids and cholesterol to apolipoproteins to form HDL cholesterol. Mutations in ABCA1 have been associated with low levels of HDL as observed in Tangier Disease \[[@pone.0226573.ref030], [@pone.0226573.ref031]\]. There are reports of HIV treatment-naïve individuals with upregulation of ABCA1, which normalizes upon initiation of ART \[[@pone.0226573.ref028]\]. Other studies have found downregulation of ABCA1 in HIV treatment naïve individuals \[[@pone.0226573.ref032]\]. The downregulation of ABCA1 in HIV treatment-naïve individuals has been implicated on HIV Nef protein; Nef protein downregulates ABCA1 leading to impaired efflux of cholesterol resulting in intracellular accumulation of cholesterol \[[@pone.0226573.ref033]--[@pone.0226573.ref035]\]. This effect is reversed with initiation of ART \[[@pone.0226573.ref036]\].

The mean viral load of our cases was 23 (range, 20--79) copies/mL ([Table 1](#pone.0226573.t001){ref-type="table"}). Therefore, the effect of HIV via the Nef protein may not play a significant role in our cohort. Given the lack of consensus on the role of ART on ABCA1 levels and the lack of documentation of levels in patients with sustained viral suppression, we measured the level of ABCA1 expression in our cohort of patients. The mean duration of therapy among cases was 4.77 (range, 1--7.5) years. We observed an upregulation of ABCA1 gene expression in cases as compared to healthy controls. Is it plausible that the continued exposure to ART in our cohort led to upregulation of ABCA1?

It is also interesting that we found upregulation in the expression levels of HMGCR mRNA and protein levels; this is counterintuitive with upregulation of ABCA1 mRNA expression (ABCA1 protein expression tended to be high but did not reach significance (p = 0.05) as the former works to increase the intracellular cholesterol levels and the latter does the opposite. A plausible explanation is that the upregulation of HMGCR is the inciting event that results in intracellular cholesterol accumulation, especially given that the increased gene expression of ABCA1 does not reflect in protein expression. Thus, the cell, in an attempt to restore homeostasis, increases the gene expression of ABCA1. This hypothesis suggests then that if the cell is unable to cause an increase in ABCA1 protein levels, it could face the dilemma of intracellular cholesterol accumulation, a harbinger of MetS.

Another possible explanation could be that there is dysregulation of cholesterol biosynthesis. We cannot tease out this conundrum without intracellular cholesterol levels. However, the serum levels of cholesterol in cases were within normal range (based on the American Cardiology Society recommendations) implying the increase in ABCA1 mRNA expression likely predates clinically observable cholesterol perturbation ([Table 2](#pone.0226573.t002){ref-type="table"}).

In the absence of intracellular cholesterol data, we performed a correlation analysis of mRNA expression of cholesterol biosynthesis genes. We observed a normal association of genes involved with cholesterol sensing---SREBP-2, HMGCR and LDLR in controls ([Fig 2](#pone.0226573.g002){ref-type="fig"}). In cases, there was negative correlation between SREBP-2 and HMGCR or LDLR ([Fig 2](#pone.0226573.g002){ref-type="fig"}). In health, SREBP-2 senses intracellular cholesterol levels and upregulates cholesterol synthesis via HMGCR and uptake from the extracellular environment via LDL receptors (LDLR) \[[@pone.0226573.ref037], [@pone.0226573.ref038]\]. Our finding suggests a dysregulation of cholesterol biosynthesis, particularly sensing by SREBP-2 in cases.

Although, our study is one of the first studies to report potential dysregulation of cholesterol biosynthesis in HIV treatment-experienced individuals, it has several limitations. First, it is a cross-sectional study and not designed to assess causality. Second, it was an exploratory pilot sub-study with small sample size to test and generate hypotheses. Third, we did not quantify intracellular cholesterol levels to assess the effect of intracellular cholesterol on the genes studied. Fourth, the effect of HIV infection itself, say through HIV Nef protein, was not assessed since we did not have access to HIV treatment-naïve individuals with higher viral loads. We were also unable to obtain the cholesterol levels of the healthy controls, instead, we compared the cholesterol levels of our cases to the upper limit of normal as published by the American Cardiology Society. Further studies are need with larger sample size and prospective design to validate our findings.

In conclusion, if our findings are validated, cholesterol biosynthesis genes could serve as biomarkers for predicting PLWH who will develop MetS and/or other lipid abnormalities and also for monitoring of treatment response of MetS and/or other lipid abnormalities in PLWH.

Supporting information {#sec013}
======================

###### Supplementary supporting information file.

(PDF)

###### 

Click here for additional data file.
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Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

In the cross-sectional study including 18 HIV treatment-experienced individuals (cases) and 18 HIV-uninfected individuals (controls), authors investigated the association between ART and cholesterol biosynthesis genes expression, both in mRNA and protein expression level. The results showed that mRNA and protein expressions of HMGCR and ABCA1 were significantly upregulated in cases compared to controls. Furthermore, mRNA expression of SREBP-2 was positively correlated with that of HMGCR and LDLR in controls, whereas mRNA expression of SREBP-2 was negatively correlated with that of HMGCR and LDLR in cases. This exploratory pilot study might provide some evidence for the underlying mechanisms of developing cholesterol abnormality in HIV treatment-experienced patients. 

Major concerns:

1.According to the study hypothesis, ART could influence cholesterol biosynthesis gene and dysregulation of genes could cause cholesterol abnormality or MetS, the controls were supposed to be HIV-infected individuals without receiving ART, rather than HIV-uninfected individuals. If HIV-uninfected individuals were chosen as controls, we could not tell whether the association was owing to HIV infection, ART, or other factors. Also, was the status of MetS or lipid abnormality considered in the inclusion and exclusion of participants?

2.In Table 2: 

(i)The means of cholesterol, HDL, LDL and triglycerides value in controls were missing, which were essential for analysis in the study. Authors are suggested to show that. Please add the status of MetS or lipid abnormality, and it would be better than only presenting the means of lipid-related index.

(ii)Are all the continuous variables presented in mean and range, without any one in median and interquartile? We are customary to present continuous variables following normal distribution in means±SDs; otherwise, in medians (25th-75th percentile). 

(iii)Based on the statement in "Study participants and procedures", I find participants of this study were a part of participants included in reference \#17. However, the minimum age of participants in cases (age of 30) and controls (age of 32) was beyond the age range of positive controls and negative controls in reference \#17 (as it was shown in the supplementary Table 1), respectively. Clarity is required on this point. 

(iv)Please provide the corresponding full name of NRTI and NNRTI in the footnote.

3.Authors were supposed not to leave out the message"The difference of AMPK B2 mRNA expression among cases and controls were neither non-significant" in Line 159-161. How about LDLR and AMPK A1? 

4.Line 162: I am confused about how to conduct stratified analysis based on "drug type". Detailed information about this would be preferred. Considering the small total sample size, it might happen that the number of participants is too low to draw warranted conclusions, so would it be meaningful to do this analysis?

5.In "Protein expression of cholesterol biosynthesis genes in study participants" part, only participants with sufficient samples for western blot were included. My concern is about whether included participants and excluded participants were comparable in mRNA expression levels? Authors are suggested to show the result of comparison in the text.

6.Line 196-198: 

(i)Authors used linear regression model to examine correlation, which was inconsistent with the statement in "Statistical analysis" (in Line 133-134). If you specify Pearson or Spearman correlation as the method to be used, correlation coefficient with its 95% CI and P value should be reported.

(ii)"significance was noted for p values ≤ 0.05" was not accurate. P\<0.05 would be considered significant, whereas P=0.05 wouldn't be.

7.In Figure 2 (D), whether the point in upper left was outlier? Please check and explain.

8.Due to the fact that the study is a cross-sectional design, authors should be more cautious and not overwhelm the findings. Conclusion should be modified accordingly.

We would appreciate receiving your revised manuscript by Dec 01 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.
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Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.
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Ying-Mei Feng

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

10.1371/journal.pone.0226573.r002

Author response to Decision Letter 0

12 Nov 2019

Response to Reviewers' comments for manuscript \# PONE-D-19-26239

We are grateful to the reviewers for their insightful comments and suggestions for our manuscript \# PONE-D-19-26239. We have considered the suggestions and made the recommended changes. Please find an itemized response to all the issues and criticisms. Response to comments are shown in italics.

Major concerns:

1\. According to the study hypothesis, ART could influence cholesterol biosynthesis gene and dysregulation of genes could cause cholesterol abnormality or MetS, the controls were supposed to be HIV-infected individuals without receiving ART, rather than HIV-uninfected individuals. If HIV-uninfected individuals were chosen as controls, we could not tell whether the association was owing to HIV infection, ART, or other factors. Also, was the status of MetS or lipid abnormality considered in the inclusion and exclusion of participants?

Response: Thank you for this insightful comment. The best control would have been HIV treatment-naïve individuals. With the change in ART guidelines to treat all patients irrespective of CD4 count, we don't have that many treatment-naïve individuals in the clinic we enrolled from. Our cohort of cases had sustained viral suppression, which we used as proxy for limited contribution of HIV infection per se on our findings. However, we cannot rule out the effect of HIV infection, therefore, we will err on the safe side and attribute the effects to ART, HIV infection or both. We have expanded upon this in the second paragraph of the introduction (Lines 58 to 60) as well as in the discussion (Lines 239 to 241). Cases were individuals on ART without clinical and/or laboratory toxicities including MetS. We have clarified this in the methods' section: Lines 83 -- 85.

2.In Table 2:

(i)The means of cholesterol, HDL, LDL and triglycerides value in controls were missing, which were essential for analysis in the study. Authors are suggested to show that. Please add the status of MetS or lipid abnormality, and it would be better than only presenting the means of lipid-related index.

Response: Unfortunately, we do not have the lipid profiles for the healthy controls. We report the cholesterol values of the cases and compare them to the American Cardiology Society (ACS) reference ranges. We have also reported this as one of the limitations of our study (Lines 305 -307). All the patients selected in this study, had hitherto, not been diagnosed with a lipid abnormality or signs of MetS.

(ii)Are all the continuous variables presented in mean and range, without any one in median and interquartile? We are customary to present continuous variables following normal distribution in means±SDs; otherwise, in medians (25th-75th percentile).

Response: We appreciate this comment. The continuous variables are now presented in medians with 25th-75th percentiles as our data is likely non-normal in distribution (please see lines 131-135). We have also added the percentiles to the text for clarity.

(iii)Based on the statement in "Study participants and procedures", I find participants of this study were a part of participants included in reference \#17. However, the minimum age of participants in cases (age of 30) and controls (age of 32) was beyond the age range of positive controls and negative controls in reference \#17 (as it was shown in the supplementary Table 1), respectively. Clarity is required on this point.

Response: We appreciate and are grateful to the reviewer for picking up this huge discrepancy. We have corrected this discrepancy; we apologize for the error (see Table 2 and Result's section, line 141).

(iv)Please provide the corresponding full name of NRTI and NNRTI in the footnote.

Response: We have provided the full names, see lines 158 to 159.

3\. Authors were supposed not to leave out the message "The difference of AMPK B2 mRNA expression among cases and controls were neither non-significant" in Line 159-161. How about LDLR and AMPK A1?

Response: We have added a sentence about the lack of a statistically significant difference in the expression of AMPK A1 and LDLR when the respective gene expressions are compared between cases and controls (Lines 172-174).

4\. Line 162: I am confused about how to conduct stratified analysis based on "drug type". Detailed information about this would be preferred. Considering the small total sample size, it might happen that the number of participants is too low to draw warranted conclusions, so would it be meaningful to do this analysis?

Response: We initially did sub analyses but decided against it for this very reason. We have deleted that sentence.

5\. In "Protein expression of cholesterol biosynthesis genes in study participants" part, only participants with sufficient samples for western blot were included. My concern is about whether included participants and excluded participants were comparable in mRNA expression levels? Authors are suggested to show the result of comparison in the text.

Response: We appreciate this insightful comment. In comparing participants with protein expression data with those without protein expression data, there was no statistically significant difference in mRNA expression, decreasing the likelihood that the cohort of patients with western blot results represents a non-random sampling. In other words, the included and excluded participants have comparable mRNA expression levels. Please see the newly attached figure (Figure 2) as well as the addendum in the Results Section, sub-section: "Protein expression of cholesterol biosynthesis genes in study participants"(lines 198 to 202) .

6.Line 196-198:

(i)Authors used linear regression model to examine correlation, which was inconsistent with the statement in "Statistical analysis" (in Line 133-134). If you specify Pearson or Spearman correlation as the method to be used, correlation coefficient with its 95% CI and P value should be reported.

Response: Linear regression was indeed the method used to determine association and this has been corrected in the text (line 134).

(ii)"significance was noted for p values ≤ 0.05" was not accurate. P\<0.05 would be considered significant, whereas P=0.05 wouldn't be.

Response: We have adjusted our significance threshold to be P\<0.05 (line 135) and throughout the entire paper.

7.In Figure 2 (D), whether the point in upper left was outlier? Please check and explain.

Response: It is indeed an outlier. When we excluded this outlier, the data still reflected negative correlation, which is very different than the positive correlation that is expected in non-diseased states. We have included this in the text under the section on "Correlation of cholesterol biosynthesis genes in study participants" in the results (see lines 220 to 221).

8.Due to the fact that the study is a cross-sectional design, authors should be more cautious and not overwhelm the findings. Conclusion should be modified accordingly.

Response: We agree with the reviewer. We have made changes throughout the manuscript to ensure that we draw appropriate conclusions based on our results and highlight inferences as hypotheses that need to be proven.
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